Veterinary Medicines

AviPro IBD XTREME

Authorised
  • Infectious bursal disease virus, strain V217, Live
Download as PDF

Product identification

Medicine name:
АвиПро ИБД Екстрийм
AviPro IBD XTREME
Active substance:
  • Infectious bursal disease virus, strain V217, Live
Target species:
  • Chicken (chick)
Route of administration:
  • In drinking water use
  • Nebulisation use

Product details

Active substance and strength:
  • Infectious bursal disease virus, strain V217, Live
    1.50
    log 10 50% embryo infective dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate for suspension
Withdrawal period by route of administration:
  • In drinking water use
    • Chicken (chick)
  • Nebulisation use
    • Chicken (chick)
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD09
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Bulgaria
Available in:
  • Bulgaria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Lohmann Animal Health GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lohmann Animal Health GmbH
Responsible authority:
  • Bulgarian Food Safety Authority
Authorisation number:
  • 0022-1887
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 28/12/2023
Download

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 28/12/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."